+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic acid ameliorates parameters of cholestasis, but does not prevent collagen accumulation in rat secondary biliary liver fibrosis



Ursodeoxycholic acid ameliorates parameters of cholestasis, but does not prevent collagen accumulation in rat secondary biliary liver fibrosis



Journal of Hepatology 26(Suppl. 1): 184




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144792

Download citation: RISBibTeXText


Related references

Protective effect of ursodeoxycholic acid on secondary biliary cirrhosis and ethynylestradiol induced cholestasis in the rat. Clement, B And A Guillouzo (Ed ) Colloque Inserm (Institut National De La Sante Et De La Recherche Medicale), Vol 216 Aspects Cellulaires Et Moleculaires De La Cirrhose; (Inserm (National Institute Of Health And Medical Research) Colloquium, Vol 216 Cellular And Molecular Aspects Of Cirrhosis); International Conference on The Cellular And Molecular Bases Of Liver Cirrhosis, Rennes, France, July 3-5, 1991 Xv+380p Editions John Libbey Eurotext: Montrouge, France; London, England, Uk, 1992

Ursodeoxycholic acid udca decreases serum cholesterol levels ameliorates symptoms and improves biochemical parameters in pediatric patients with chronic intrahepatic cholestasis. Gastroenterology 98(5 Part 2): A566, 1990

Anticholestatic effect of ursodeoxycholic acid is not accompanied by improved histology and decreased fibrosis in rat biliary liver fibrosis. Gastroenterology 112(4 Suppl. ): A1228, 1997

Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. Journal of Pediatrics 121(1): 138-141, 1992

Failure of ursodeoxycholic acid udca to prevent the occurrence of cholestasis in benign recurrent intrahepatic cholestasis bric. Gastroenterology 98(5 Part 2): A578, 1990

24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. Journal of Hepatology 62(4): 871-878, 2015

Silymarin retards collagen accumulation in rat secondary biliary fibrosis. Journal of Hepatology 23(Suppl. 1): 142, 1995

Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 31(8): 918-921, 1990

Ofloxacin and ursodeoxycholic acid versus ursodeoxycholic acid alone to prevent occlusion of biliary stents: a prospective, randomized trial. Endoscopy 33(6): 491-494, 2001

Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sciences 79(10): 1014-1019, 2006

Tauroursodeoxycholic acid ameliorates cholestasis and tritiated PEG 4000 permeation induced by retrograde biliary injection of taurochenodeoxycholic acid in perfused rat liver. Hepatology 18(4 Part 2): 294A, 1993

Antifibrogenic effect of ursodeoxycholic acid cyclosporin a penicillamine prednisolone and colchicine in a rat model of secondary biliary fibrosis. Hepatology 10(4): 630, 1989

Ursodeoxycholic acid udca treatment improves liver disease and nutritional state in cystic fibrosis cf patients with chronic cholestasis. Gastroenterology 96(5 Part 2): A586, 1989

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32(6): 1196-1199, 2000

Ursocholic acid, a hydrophilic bile acid, fails to improve liver function parameters in primary biliary cirrhosis: comparison with ursodeoxycholic acid. American Journal of Gastroenterology 92(6): 1035-1037, 1997